Resultados de la búsqueda

Falk E, Sillesen H, Muntendam P, Fuster V. The High-Risk Plaque Initiative: Primary Prevention of Atherothrombotic Events in the Asymptomatic Population. Curr Atheroscler Rep (2011) 13:359-66

Fuster V, Sanz G. [Fixed-dose compounds and the secondary prevention of ischemic heart disease] Rev Esp Cardiol (2011) 64:3-9

Franco M, Cooper R, Bilal U, Fuster V. Control of Coronary Heart Disease Risk Factors and Evidence-Based Therapies: Joint Efforts for Coronary Heart Disease Prevention in Spain. Rev Esp Cardiol (2011) 64:962-4

Sanz G, Fuster V. Polypill and global cardiovascular health strategies. Semin Thorac Cardiovasc Surg. (2011) 21:24-9

Sanz J, Fuster V. Update in Cardiology. Ann Intern Med (2010) 152:786-91

Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol (2010) 55:1487-98

Zaitsev S, Spitzer D, Murciano JC, Ding BS, Tliba S, Kowalska MA, Marcos-Contreras OA, Kuo A, Stepanova V, Atkinson JP, Poncz M, Cines DB, Muzykantov VR. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 115:5241-8

Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol (2009) 53:2315-23

Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med (2009) 6:101-10

Farkouh ME and Fuster V. Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med (2009) 6:1